Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is an intractable
disease and most cases harbor genetic alterations that activate JAK or ABL signaling. The …

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk
ALL subtype with high rates of relapse and poor patient outcome. Activating mutations …

Philadelphia chromosome-like acute lymphoblastic leukemia (“Ph-like ALL”) is a subtype of
high-risk B-precursor ALL (B-ALL) that carries a high risk of relapse after conventional …

Patients with cytokine receptor-like factor 2 rearranged (CRLF2-re) subgroup Philadelphia
chromosome–like B-cell acute lymphoblastic leukemia (Ph-like B-ALL) have a high relapse …

Background: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a
high-risk subtype occurring in 15-30% of older children and adolescents/young adults …

Abstract CRLF2 rearrangements, JAK1/2 point mutations, and JAK2 fusion genes have been
identified in Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL), a …

Acute lymphoblastic leukemia (ALL) harboring the IgH-CRLF2 rearrangement (IgH-CRLF2-
r) exhibits poor clinical outcomes and is the most common subtype of Philadelphia …

Abstract CRLF2-rearranged (CRLF2 r) acute lymphoblastic leukemia (ALL) accounts for
more than half of Philadelphia chromosome-like (Ph-like) ALL and is associated with a poor …

Introduction: Systems biology approaches can identify critical dependencies in complex
cancer signaling networks to inform rational therapy combinations and overcome treatment …

Adults and children with high-risk CRLF2-rearranged acute lymphoblastic leukemia (ALL)
respond poorly to current cytotoxic chemotherapy and suffer unacceptably high rates of …